COMMUNIQUÉS West-GlobeNewswire

Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer’s Disease Candidate

01/03/2018 - 14:05

TUSTIN, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) (NASDAQ: CDMOP ), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

01/03/2018 - 14:00

FIT Biotech Oy Company release March 1, 2018 at 03:00 PM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on December 22, 2017 [...]

Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in the United Kingdom

01/03/2018 - 14:00

BILLERICA, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS ), a medical technology company that offers joint replacement implants designed and manufactured to fit and conform to each patient’s [...]

aTyr Pharma to Present at Two Upcoming Investor Conferences in March

01/03/2018 - 14:00

SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]

Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors

01/03/2018 - 14:00

SAN CARLOS, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) [...]

Onconova to Present Dose Optimization Studies with Rigosertib Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium

01/03/2018 - 14:00

Exploration of dose and schedule of administration in an expanded Phase 2 trial with the objective of designing a pivotal Phase 3 trial Risk-mitigation strategies to reduce the incidence of urinary tract adverse events [...]

India Globalization Capital Partners with Parkinson’s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)

01/03/2018 - 14:00

BETHESDA, Md., March 01, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) today announces that it has signed a Joint Development and Services Agreement with the prestigious Parkinson’s [...]

Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2017 Financial Results Call for March 8

01/03/2018 - 14:00

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX ), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, [...]

athenahealth @ HIMSS18: Healthcare Providers, Care Staff, and Leadership Are Finally Being Freed from Administrative Burden

01/03/2018 - 14:00

Also: Sneak Peek Epocrates Connect, A Universal Mobile App Designed to End Industry’s Status Quo EHR Experience and Unleash Unparalleled Access to Clinical Information On Stage: CEO Jonathan Bush Hosts Thomas Jefferson [...]

scPharmaceuticals Inc. to Present at the Cowen 38th Annual Health Care Conference

01/03/2018 - 14:00

BURLINGTON, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH ), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused [...]

FDA Accepts REMOXY® NDA for Review, Sets PDUFA Date of August 7, 2018

01/03/2018 - 14:00

AUSTIN, Texas, March 01, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE ) announced today that the U.S. Food and Drug Administration (FDA) has determined that a New Drug Application (NDA) for REMOXY ER, [...]

Spero Therapeutics to Present at March Investor Conferences

01/03/2018 - 14:00

CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO ), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel [...]

Woebot Secures $8 Million in Funding to Increase Access to Mental Health Care Worldwide

01/03/2018 - 13:30

SAN FRANCISCO, March 01, 2018 (GLOBE NEWSWIRE) -- Today, Woebot Labs, Inc. announced an $8 million Series A funding round from leading venture capital firm New Enterprise Associates (NEA) with participation from Andrew [...]

Otonomy to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update

01/03/2018 - 13:30

SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC ), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial [...]

BioCorRx Schedules Business Update Conference Call

01/03/2018 - 13:30

ANAHEIM, CA, March 01, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it will [...]

Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights

01/03/2018 - 13:30

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI ) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today reported financial [...]

CareDx to Refinance Debt with Perceptive Advisors

01/03/2018 - 13:30

Balance Sheet to be Simplified with Single Term Loan BRISBANE, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ), a molecular diagnostics company focused on the discovery, development and [...]

Myriad Genetics Demonstrates Strong Commitment to Preventing Hereditary Colon Cancer as Part of National Colorectal Cancer Awareness Month

01/03/2018 - 13:05

SALT LAKE CITY, March 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary [...]

ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting

01/03/2018 - 13:01

Oral administration of OBE022 shows favorable safety and results in predictable exposure Non-clinical results of OBE022 for PTL demonstrating fetal safety Geneva, Switzerland and Boston, MA - 01 March 2018 - ObsEva SA ( [...]